Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans.
Topical application of the 5-HT3 receptor antagonist ondansetron (50-250 microg) delivered in a pluronic lecithin organogel vehicle (PLO, 0.5 ml) produced dose-dependent attenuation of nociceptive and inflammatory effects of intradermally injected capsaicin (10 microg/10 microl) in humans. Significant, dose-dependent analgesic effects were produced by 100 microg and 250 microg doses of ondansetron; these doses also reduced mechanical hyperalgesia produced by capsaicin. However, only 250 microg dose of ondansetron diminished capsaicin-induced inflammatory flare.
Giordano
J
J
Pain Clinic, HealthSouth Rehabilitation Hospital, Beaumont, TX 77707, USA. jgiordano@gtenet.com
Daleo
C
C
Sacks
S M
SM
D000287:Administration, Topical; D002211:Capsaicin; D003877:Dermatitis, Contact / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005782:Gels / Q000008:administration & dosage; D006801:Humans; D007271:Injections, Intradermal; D009619:Nociceptors / Q000187:drug effects*; D017294:Ondansetron / Q000008:administration & dosage*; D010147:Pain Measurement / Q000187:drug effects; D010713:Phosphatidylcholines / Q000008:administration & dosage; D012702:Serotonin Antagonists / Q000008:administration & dosage*
D005782:Gels; D010713:Phosphatidylcholines; D012702:Serotonin Antagonists; D017294:Ondansetron; D002211:Capsaicin